Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Ataxia telangiectasia and Rad3-related (ATR) kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS), and has been considered as a potential target for cancer therapy. Herein, we report the discovery of a series of 6,7-dihydro-5H-pyrrolo[3,4-d]-pyrimidine derivatives as a new class of ATR inhibitors. Among them, compound 5g exhibits an IC value of 0.007 μM against ATR kinase. In vitro, 5g displays good anti-tumor activity and could significantly reduce the phosphorylation level of ATR and its downstream signaling protein. Overall, this study provides a promising lead compound for subsequent drug discovery targeting ATR kinase.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2022.128651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DDR kinase inhibition causes hypersensitivity to Taxol through caspase-3 activation.
Biochem Biophys Res Commun
August 2025
Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, USA. Electronic address:
Taxol is an antitumor agent that arrests cells in the late G2 and M phases of the cell cycle. Our previous research demonstrated that PARP inhibition enhances Taxol-induced cell death via oxidative stress and free radical production. In this study, we hypothesized that the inhibiting DNA damage response (DDR) kinases would further increase Taxol cytotoxicity by impairing the repair of Taxol-induced DNA damage.
View Article and Find Full Text PDFMutational profile of oropharyngeal squamous cell carcinoma in relation to HPV, tobacco smoking and prognosis with validation in the DAHANCA 19 randomized trial.
Acta Oncol
August 2025
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark; Department of Clinical Medicine, Health, Aarhus University, Denmark.
Background And Purpose: This study investigated prognostic biomarkers in oropharyngeal squamous cell carcinoma (OPSCC), with a focus on tumors related to human papillomavirus (HPV) infection and potential molecular effects of tobacco smoking, as smokers with HPV+ OPSCC often have poorer outcomes.
Patients/material And Methods: We first analyzed 56 previously untreated OPSCC patients (exploration cohort), assessing HPV status, gene expression related to hypoxia, tumor subtype, and radiosensitivity, together with next-generation sequencing (NGS) of cancer-related genes. A custom NGS panel was subsequently designed and validated in 162 patients from the DAHANCA 19 randomized controlled trial (RCT), all treated with curative (chemo-)radiotherapy.
Inhibiting the DNA damage repair of HNSCC cells in combination with normo-fractionated radiotherapy influences clonogenicity, senescence and expression of NK cell activation markers.
Sci Rep
August 2025
Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstrasse 27, Erlangen, 91054, Germany.
Treatment of head and neck squamous cell carcinomas (HNSCC) remains challenging with regards to radioresistance, particularly of Human Papilloma Virus (HPV)-negative tumors. Several new approaches are currently under pre-clinical and clinical investigation. Combination of radiotherapy (RT) and kinase inhibitors of the DNA damage repair system (DDRi), targeting Ataxia Telangiectasia Mutated (ATM) or ATM and Rad3-related (ATR), are promising, but the consequences on tumor cell phenotype are still scarce.
View Article and Find Full Text PDFATR-CHK1 Axis Inhibitors in Gastric Cancer Treatment.
Int J Mol Sci
August 2025
Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
Gastric cancer remains a significant global health challenge, with regional and demographic disparities in incidence, mortality, and treatment outcomes. Despite advances in screening and early detection, prognosis remains poor for many patients, particularly those with advanced disease. Recent insights into DNA damage response pathways have uncovered critical molecular vulnerabilities in gastric tumors, including frequent mutations, loss, deficiency, and oncogene-driven replication stress, which render these cancers highly dependent on the ATR-CHK1 axis for survival.
View Article and Find Full Text PDFIntegrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Clin Pharmacol Ther
August 2025
EMD Serono, Billerica, Massachusetts, USA.
We present model-informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153). A population PK (POPPK) model was developed to characterize PK and hemoglobin (HGB) reduction after multicycle treatment was simulated using a semi-mechanistic, multivariate POPPK/PD model of reticulocyte (RET), red blood cell (RBC), and HGB dynamics. A semi-mechanistic PK-efficacy model characterized concentration-dependent tumor growth inhibition (TGI) in ARID1A mutant xenograft models.
View Article and Find Full Text PDF